BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Truist Financial Analyst Says

BridgeBio Pharma (NASDAQ:BBIO) had its target price upped by equities research analysts at Truist Financial from $86.00 to $95.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 44.67% from the company’s previous close.

Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Oppenheimer upped their price target on BridgeBio Pharma from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Raymond James Financial set a $89.00 price target on BridgeBio Pharma and gave the stock an “outperform” rating in a report on Thursday, February 12th. Sanford C. Bernstein initiated coverage on BridgeBio Pharma in a report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price objective for the company. Finally, Morgan Stanley increased their target price on BridgeBio Pharma from $96.00 to $98.00 and gave the stock an “overweight” rating in a report on Wednesday. Twenty-two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.50.

BridgeBio Pharma Trading Down 3.9%

NASDAQ:BBIO traded down $2.65 during mid-day trading on Wednesday, hitting $65.67. 2,480,744 shares of the company’s stock were exchanged, compared to its average volume of 3,267,873. BridgeBio Pharma has a fifty-two week low of $28.33 and a fifty-two week high of $84.94. The firm has a market capitalization of $12.65 billion, a P/E ratio of -15.75 and a beta of 1.13. The company has a 50 day simple moving average of $75.24 and a 200-day simple moving average of $64.53.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million for the quarter, compared to analysts’ expectations of $150.71 million. The business’s revenue was up 2521.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.40) earnings per share. As a group, analysts expect that BridgeBio Pharma will post -3.67 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Neil Kumar sold 28,053 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $71.39, for a total value of $2,002,703.67. Following the completion of the sale, the chief executive officer owned 234,451 shares in the company, valued at $16,737,456.89. This represents a 10.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the sale, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This represents a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 204,174 shares of company stock worth $15,012,335. 18.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of BridgeBio Pharma in the 2nd quarter worth approximately $25,000. Aster Capital Management DIFC Ltd bought a new stake in BridgeBio Pharma during the third quarter worth $31,000. Harvest Fund Management Co. Ltd purchased a new position in BridgeBio Pharma in the third quarter worth $34,000. Jones Financial Companies Lllp purchased a new position in BridgeBio Pharma in the first quarter worth $35,000. Finally, First Horizon Corp purchased a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at $36,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Morgan Stanley raised its price target to $98 and kept an “overweight” rating, implying roughly ~47% upside vs. the current price — a clear buy-side signal that can support the stock. Benzinga
• Positive Sentiment: BridgeBio reported Q4 revenue of $154.2M vs. ~$150.7M expected and revenue was up ~2,521% year‑over‑year — evidence of commercial traction (Attruby was highlighted in the company release), which reduces near‑term execution risk. GlobeNewswire
• Positive Sentiment: Several Wall Street shops have been raising targets recently (Cantor Fitzgerald, HC Wainwright, Goldman and others noted), which can attract momentum buyers and support higher valuations. MarketBeat analyst roundup
• Neutral Sentiment: Full Q4 earnings call/transcripts are available — useful for details on Attruby uptake, guidance and pipeline timelines; these may provide follow‑up catalysts but are informational until new guidance or data appear. Yahoo Finance transcript
• Negative Sentiment: BridgeBio missed on EPS: reported a ($1.00) loss vs. ($0.75) expected — the wider-than-expected loss is pressuring near-term sentiment despite the revenue beat. Zacks
• Negative Sentiment: CEO Neil Kumar sold 28,053 shares (recently part of several sales), a sizable insider disposition that can raise short-term investor caution even if filings show he retains a large stake. InsiderTrades / SEC filing

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.